Sandoz inks biosimilars commercialization deal with Gan & Lee Pharmaceutical
The production capacity of florfenicol raw materials is limited or there may be an oversold rebound.
After the Spring Festival, as the veterinary raw material drug market rose to a high level, the market began to weaken, and the veterinary raw material drug market showed a downward trend. However, with the arrival of the peak season for traditional demand, the veterinary raw material drug market may rebound.
Among the Veterinary Raw Materials monitored by the China Veterinary Drug and Feed Trading Center, the market prices of many varieties have dropped significantly.

However, with the advent of summer, the market trend of veterinary drug raw materials may usher in a wave of rebound, and the prices of some products may enter an upward channel.
First, the veterinary raw material drug market is about to enter the peak season of traditional demand, and the downstream market demand is gradually increasing. The rigid demand restricts the downside of the raw material drug market.
Second, the cumulative increase in external factors, environmental protection, security inspections and other factors may cause some companies to restrict or even stop production, and the supply of veterinary raw materials in the veterinary drug market has tightened. The upstream raw material plant of FLORFENICOL has been suspended due to environmental protection. Recently, the news has been released. The florfenicol plant has a high price mentality, and the market has responded positively and focused attention.
Third, the summer high temperature maintenance season is coming. Historical data shows that the high temperature maintenance of mainstream manufacturers will have a greater impact on product market prices.
Fourth, the early-stage demand has weakened, shipments are not smooth, intermediate channels have reduced prices for shipments, withdrawn funds, some channels have been oversold, and inventories have dropped to low levels. Once market demand improves, full replenishment of the industry chain will be triggered, which may be promoted by then Product prices are rising rapidly.
2026-10-17
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
24th Pharma Asia International Exhibition & Conferences to Open in Karachi, Pakistan
-
India Proposes New GMP Rules for Clinical Trial and API Manufacturing
-
CPHI & PMEC India 2026
-
8th Annual Pharma Manufacturing and Automation Convention 2026
-
Pharma Manufacturing & Automation Excellence Awards 2026
-
CPHI Korea 2026: A Leading Gateway to Korea’s Pharmaceutical and Biopharma Market
-
Pharmaconex
-
Pharma Quality Excellence Awards 2026 - Celebration and Conclusion
-
Pharma Quality Reimagined: Highlights from the 6th Annual Pharma GMP & Quality Management 2026
-
From Feedmill to Food System: VIV Europe 2026 Addresses the Industry's Most Critical Challenges
Recommend Reading
-
Pfizer Warns Germany: Drug Pricing Could Put Investment at Risk
-
Unilever Reports Stronger Margins and Accelerated Portfolio Transformation in FY2025
-
BASF-Evonik Takeover Faces Political Resistance as German State Defends Jobs and Independence
-
When BASF Lets Agriculture Fly Solo: A Capital Repricing of Scale and Ambition
-
J&J VAT Dispute Threatens Free Medicine Access in Britain
-
Business Society September 7, 2026 Ethanol Market View: Strong Consolidation
-
Supply and Demand Easing Coupled with Bearish Moving Averages, Melamine Spot Prices Continue to Weaken in China
-
Business Society’s Market Outlook for China’s Hydrofluoric Acid on August 20, 2026: A Volatile Pattern
-
Business Society’s Market Outlook for Maleic Anhydride on September 7, 2026: Volatile
-
U.S. Finds Methionine Dumping Could Recur, With Japan Margin Up to 76.50%